# Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

> **NCT07570849** · PHASE2 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Chidamide, Gemcitabine, cisplatin, immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT07570849
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570849, "Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07570849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*